F&V Capital Management Boosts Stake in AxoGen, Inc.

The investment firm increased its position in the medical equipment provider by over 176,000 shares.

Apr. 2, 2026 at 8:35am

Got story updates? Submit your updates here. ›

F&V Capital Management LLC purchased a new position of 176,995 shares in AxoGen, Inc. (NASDAQ:AXGN) during the fourth quarter, according to a recent SEC filing. The firm's investment in the medical equipment provider is now valued at approximately $5.79 million, making up about 0.9% of its portfolio.

Why it matters

AxoGen is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. The company's core products include the Avance Nerve Graft and Axoguard Nerve Connector and Protector devices. This investment by F&V Capital Management signals confidence in AxoGen's growth potential within the medical device market.

The details

According to the 13F filing, F&V Capital Management purchased the 176,995 shares of AxoGen stock in the fourth quarter of 2025. This new position represents 0.38% ownership of the company. The investment firm cited AxoGen's innovative nerve repair products and growth prospects as factors behind the increased stake.

  • F&V Capital Management filed the 13F disclosure for the fourth quarter of 2025 on April 2, 2026.
  • The firm purchased the 176,995 shares of AxoGen stock during the fourth quarter of 2025.

The players

F&V Capital Management LLC

An investment management firm that purchased a new position in shares of AxoGen, Inc.

AxoGen, Inc.

A Florida-based medical technology company that develops surgical solutions for peripheral nerve damage, including the Avance Nerve Graft and Axoguard product lines.

Got photos? Submit your photos here. ›

The takeaway

This investment by F&V Capital Management underscores the market's confidence in AxoGen's medical device technology and its potential to capture a larger share of the peripheral nerve repair market.